KRAS and colorectal cancer: The FDA acknowledged the evidence base for KRAS presence as a marker for patients who would achieve no benefit from anti-EGFR therapy and issued a label update for the entire class of drugs, recommending KRAS testing as part of colorectal cancer patient management (Amado et al., 2008).